Phase II study of axitinib intensification compared to nivolumab alone after induction with ipilimumab plus nivolumab in patients with mRCC without previous complete response (AxIn study).

被引：0

作者：

Ciccarese, Chiara

Verzoni, Elena

Bimbatti, Davide

Buti, Sebastiano

Calabro, Fabio

Galli, Luca

Scagliarini, Sarah

Fornarini, Giuseppe

Baldessari, Cinzia

Bilancia, Domenico

Facchini, Gaetano

Cattrini, Carlo

Masini, Cristina

Giganti, Maria Olga

Scandurra, Giuseppa

Nole, Franco

Berruti, Alfredo

Milella, Michele

Antonuzzo, Lorenzo

Iacovelli, Roberto

机构：

[1] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Oncol Unit, Rome, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[3] IOV IRCCS, Ist Oncol Veneto, Oncol Unit 1, Padua, Italy

[4] Univ Hosp Parma, Fontevivo, Italy

[5] IFO Ist Regina Elena, Rome, Italy

[6] Univ Pisana, UO Oncol Med 2 Univ Azienda Osped, Pisa, Italy

[7] Cardarelli Hosp, Dept Oncol, Naples, Italy

[8] IRCCS Osped Policlin San Martino, Genoa, Italy

[9] Azienda Osped Univ Policlin Modena, Oncol Unit, Modena, Italy

[10] Azienda Osped S Carlo, Potenza, Italy

[11] SM delle Grazie Hosp, Med Oncol Unit, Pozzuoli, Italy

[12] Azienda Osped Maggiore Carita, Novara, Italy

[13] AUSL IRCCS Reggio Emilia, Reggio Emilia, Italy

[14] Osped Cremona, Cremona, Italy

[15] Humanitas Ctr Catanese Oncol, Catania, Italy

[16] IRCCS Ist Europeo Oncol, Milan, Italy

[17] Univ Brescia, Dept Med & Surg Special Radiol Sci & Publ Hlth, Med Oncol Unit, ASST Spedali Civili, Brescia, Italy

[18] Univ Verona, Sch Med, Sect Oncol, Verona, Italy

[19] Verona Univ Hosp Trust, Verona, Italy

[20] Sodc Ematol Azienda Osped Careggi, Florence, Italy

[21] Fdn Policlin Univ A Gemelli, IRCCS, Rome, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

283-2494-9200; 261-492-3532-2370-7650-2700; 261-492-11294; 261-492-3532-2370; 261-492-3532-2373; 261-492-5651-9270-5652; 261-492-5651-9270-5657; 4; 3; 2; 14; 319; 3581; 137; 3585; 8; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.TPS494

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：TPS494 / TPS494

页数：1

共 50 条

[1] A phase II study to evaluate the safety, pharmacodynamics and efficacy of entinostat in combination with nivolumab plus ipilimumab in patients with renal cell carcinoma previously treated with nivolumab plus ipilimumab or nivolumab alone.
Pili, Roberto
Adra, Nabil
Logan, Theodore F.
Burney, Heather
Atkins, Michael B.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[2] Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC
Omar Kaseb, Ahmed
Duda, Dan G.
Tran Cao, Hop Sanderson
Abugabal, Yehia I.
Vence, Luis M.
Rashid, Asif
Pestana, Roberto
Blando, Jorge M.
Singh, Shalini
Vauthey, Jean-Nicolas
Hassan, Manal
Amin, Hesham M.
Qayyum, Aliya
Shin Chun, Yun
David Tzeng, Ching-Wei
Sakamuri, Divya
Wolff, Robert A.
Yao, James C.
Patrick Allison, James
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[3] A Phase II Study of Nivolumab or Ipilimumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 11 - 12
[4] 009 Randomized, open -label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Kaseb, A.
Vence, L.
Blonde, J.
Yadav, S.
Pestana, R.
Vauthey, J.
Cao, H.
Chun, Y.
Sakamura, D.
Wolff, R.
Yoe, J.
Allison, J.
Sharma, P.
ANNALS OF ONCOLOGY, 2019, 30
[5] Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Kaseb, A.
Duda, D. G.
Cao, H. S. Tran
Abugabal, Y. I.
Vence, L. M.
Rashid, A.
Pestana, R. Carmagnani
Blando, J. M.
Singh, S.
Vauthey, J. N.
Chun, Y. S.
Tzeng, C-W. D.
Sakamuri, D.
Wolff, R. A.
Yao, J. C.
Allison, J.
Sharma, P.
ANNALS OF ONCOLOGY, 2019, 30 : 880 - 880
[6] Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
Kaseb, Ahmed Omar
Pestana, Roberto Carmagnani
Vence, Luis M.
Blando, Jorge M.
Singh, Shalini
Ikoma, Naruhiko
Raghav, Kanwal Pratap Singh
Sakamuri, Divya
Girard, Lauren
Tan, Dongfeng
Vauthey, Jean-Nicolas
Tzeng, Ching-Wei David
Aloia, Thomas A.
Chun, Yun Shin
Yao, James C.
Wolff, Robert A.
Allison, James Patrick
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[7] Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
Kaseb, Ahmed Omar
Pestana, Roberto Carmagnani
Vence, Luis M.
Blando, Jorge M.
Singh, Shalini
Ikoma, Naruhiko
Vauthey, Jean-Nicolas
Allison, James Patrick
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
[8] Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
Kaseb, Ahmed Omar
Cao, Hop Sanderson Tran
Mohamed, Yehia, I
Qayyum, Aliya
Vence, Luis M.
Blando, Jorge M.
Singh, Shalini
Lee, Sunyoung S.
Raghav, Kanwal Pratap Singh
Altameemi, Lina
Rashid, Asif
Vauthey, Jean-Nicolas
Carter, Kristen
Tzeng, Ching-Wei David
Chun, Yun Shin
Yao, James C.
Wolff, Robert A.
Allison, James Patrick
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
Kaseb, Ahmed Omar
Pestana, Roberto Carmagnani
Vence, Luis M.
Blando, Jorge M.
Singh, Shalini
Ikoma, Naruhiko
Vauthey, Jean-Nicolas
Allison, James Patrick
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[10] Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).
Zibelman, Matthew R.
Geynisman, Daniel M.
Molina, Ana M.
Malizzia, Lois
Devarajan, Karthik
Luong, Diana
Sullivan, Elizabeth
Carducci, Michael Anthony
Plimack, Elizabeth R.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →